Table 1 Clinical characteristics of study subjects.
| Â | Pre-bedrest baseline | Day 21 of bedrest | p-value |
|---|---|---|---|
Bedrest group | |||
N | 11 | 11 | Â |
Total cholesterol (mg/dL) | 143.5 ± 20.0 | 122.0 ± 21.2 | 0.001 |
HDL-cholesterol (mg/dL) | 36.8 ± 6.7 | 30.0 ± 6.8 | 0.001 |
LDL-cholesterol (mg/dL) | 90.2 ± 15.9 | 79.6 ± 16.1 | 0.040 |
Total triglyceride (mg/dL) | 82.6 ± 19.8 | 62.2 ± 13.3 | 0.014 |
Plasma apoA-I (mg/dL) | 120.4 ± 13.7 | 97.8 ± 14.9 | 0.001 |
Plasma apoA-II (mg/dL) | 36.0 ± 4.2 | 30.4 ± 2.8 | 0.002 |
Plasma SAA (mg/dL) | 0.5 (0.2–0.6) | 0.3 (0.2–0.9) | 0.624 |
Bedrest plus RVE group | |||
N | 11 | 11 | Â |
Total cholesterol (mg/dL) | 161.1 ± 28.1 | 130.2 ± 24.4 | 0.002 |
HDL-cholesterol (mg/dL) | 38.3 ± 6.7 | 29.8 ± 5.0 | 0.001 |
LDL-cholesterol (mg/dL) | 102.9 ± 22.2 | 87.4 ± 20.0 | 0.029 |
Total triglyceride (mg/dL) | 99.8 ± 34.7 | 65.1 ± 16.8 | 0.002 |
Plasma apoA-I (mg/dL) | 127.3 ± 16.6 | 97.3 ± 9.5 | 0.001 |
Plasma apoA-II (mg/dL) | 39.1 ± 3.2 | 30.6 ± 3.1 | 0.001 |
Plasma SAA (mg/dL) | 0.8 (0.5–1.0) | 0.8 (0.5–1.0) | 0.966 |
